Abstract: The present invention provides screening methods which may be regarded as in vitro or ex vivo methods of interrogating the immune system to understand what viral antigens are “seen” and responded to by T cells of the immune systems during viral infection. The screening methods further link in vitro or ex vivo responses to progression of infection in subjects.

Abstract: The present invention provides the use of nanoparticles of a compound of general formula MnXy, where M is (i) a metal selected from the group consisting of Calcium (Ca), Aluminium (Al), Zinc (Zn), Nickel (Ni), Tungsten (W) or Copper (Cu); or (ii) a non-metal selected from the group consisting of Silicon (Si), Boron (B) or Carbon (C); in which n is equal to 1, 2, or 3, and X is (iii) a non-metal selected from the group consisting of Oxygen (O), Nitrogen (N), or Carbon (C); or (iv) an anion selected from the group consisting of phosphate (PO43?), hydrogen phosphate (HPO42?), dihydrogen phosphate (H2PO4?), carbonate (CO3), silicate (SiO42?), sulphate (SO42?), nitrate (NO3?), nitrite (NO2?); in which y is equal to 0, 1, 2, 3 or 4; for use in reducing and/or preventing virus transmission. Articles of protective clothing or filters are provided in which the fibres are coated with said nanoparticles for use in reducing and/or preventing virus transmission.

Abstract: The use of a composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol in the preparation of a medicament for the treatment or prevention of HIV viral infections.

Abstract: The present invention relates to the production of vaccines having improved safety, particularly to a process therefor which allows even an AIDS vaccine to be manufactured, comprising in order, the steps of:a) treating the virus with a general inactivating agent;b) deaggregating the virus with a suitable solvent or detergent;c) treating the virus with an RNA and/or DNA inactivating agent; andd) stabilizing the virus with a suitable cross-linking agent.